Haimovis 24mg/3ml syringe

Haimovis® is a hydrogel that is produced according to Good Manufacturing Practice (GMP) and contains HYADD®4, a new molecule patented by Fidia, at a concentration of 8 mg/ml. HYADD®4 is a new hyaluronic acid derivative: partial hyaluronic acid hexadecylamide (partial due to the very low level of hyaluronic acid modification, at approximately 3% molar concentration to maintain biocompatibility).

This structure gives Haimovis® special properties including a long retention time and visco-elastic properties in addition to the excellent lubricating properties of the preparation.

Restoration of elasticity. In contrast to cross-linked hyaluronic acid, Haimovis® exhibits complete restoration of its elasticity after repeated mechanical stress, which translates into a more pronounced ability to absorb shock caused by mechanical loading to better protect the joint.

Excellent biotribological properties. The biotribological properties are related to the ability of the substance to lubricate the cartilage surfaces upon mutual contact and thus protect them from the friction and mechanical stress caused by movement.

Hydrogels may have similar viscosity-elasticity coefficients but that does not mean they have the same lubricating effects inside the joint.
The Chemovis preparation shows the best lubricating properties among natural and cross-linked polymers both in healthy cartilage simulation and in degraded cartilage. The physicochemical and biological properties described for Haimovis form the basis of the clinical efficacy that has been found for this drug in the treatment of osteoarthritis and makes it the drug of choice for the treatment of acute and traumatic chondropathy in professional and amateur athletes.

Restoration of synovial fluid viscosity by Haimovis® effectively reduces pain, restores and preserves joint function in patients with osteoarthritis of the shoulder joint Biomechanical and biological features of Haimovis® create prerequisites for expanding indications for its use in diseases caused by sports activities.

Indications

For intra-articular administration in trauma and in sports medicine

Active ingredient

Sodium hyaluronate

Composition

The main component of the Heimovis medical device 24 mg / 3 ml pre-filled syringe is sodium hyaluronate hexadecylamide (HYADD®4) obtained by amidizing the carboxyl group of sodium hyaluronate with hexadecylamine.

List of initial materials: – HYADD®4 (sodium hyaluronate hexadecylamide) – 24 mg;

– sodium chloride -25.5 mg;

– sodium hydrophosphate dodecahydrate (Na2HP04 x 12H20) – 1.35 mg;

– sodium dihydrophosphate dihydrate (Na2HP04 x 2H20) – 0.33 mg;

– water for injection up to 3 ml (q.s.).

Directions for use

The medical device “Haimovis” is injected using a sterile needle (18 or 20 gauge) into the affected joint (see Figure 1) once a week, the treatment course does not exceed 3 weeks.

Repeated courses can be carried out if necessary.

A single treatment usually consists of injecting the medical device “Haimovis” into 1 large, or 2 medium, or 3-5 small joints.